Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Estrogen Receptor pathway activity score to predict clinical response or resistance to neo-adjuvant endocrine therapy in primary breast cancer.

Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet SL, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A.

Mol Cancer Ther. 2019 Nov 14. pii: molcanther.0318.2019. doi: 10.1158/1535-7163.MCT-19-0318. [Epub ahead of print]

PMID:
31727690
2.

Artificial Intelligence in Clinical Health Care Applications: Viewpoint.

van Hartskamp M, Consoli S, Verhaegh W, Petkovic M, van de Stolpe A.

Interact J Med Res. 2019 Apr 5;8(2):e12100. doi: 10.2196/12100.

3.

Quantitative Measurement of Functional Activity of the PI3K Signaling Pathway in Cancer.

van de Stolpe A.

Cancers (Basel). 2019 Mar 1;11(3). pii: E293. doi: 10.3390/cancers11030293.

4.

Author Correction: Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics.

Taskesen E, Huisman SMH, Mahfouz A, Krijthe JH, de Ridder J, van de Stolpe A, van den Akker E, Verhaegh W, Reinders MJT.

Sci Rep. 2018 Nov 23;8(1):17304. doi: 10.1038/s41598-018-35518-w.

5.

Assessment of Functional Phosphatidylinositol 3-Kinase Pathway Activity in Cancer Tissue Using Forkhead Box-O Target Gene Expression in a Knowledge-Based Computational Model.

van Ooijen H, Hornsveld M, Dam-de Veen C, Velter R, Dou M, Verhaegh W, Burgering B, van de Stolpe A.

Am J Pathol. 2018 Sep;188(9):1956-1972. doi: 10.1016/j.ajpath.2018.05.020. Epub 2018 Jul 6.

6.

Tumor-Specific Mitochondrial DNA Variants Are Rarely Detected in Cell-Free DNA.

Weerts MJA, Timmermans EC, van de Stolpe A, Vossen RHAM, Anvar SY, Foekens JA, Sleijfer S, Martens JWM.

Neoplasia. 2018 Jul;20(7):687-696. doi: 10.1016/j.neo.2018.05.003. Epub 2018 May 26.

7.

Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.

Spaan I, Raymakers RA, van de Stolpe A, Peperzak V.

J Hematol Oncol. 2018 May 18;11(1):67. doi: 10.1186/s13045-018-0615-3. Review.

8.

Towards a 21st-century roadmap for biomedical research and drug discovery: consensus report and recommendations.

Langley GR, Adcock IM, Busquet F, Crofton KM, Csernok E, Giese C, Heinonen T, Herrmann K, Hofmann-Apitius M, Landesmann B, Marshall LJ, McIvor E, Muotri AR, Noor F, Schutte K, Seidle T, van de Stolpe A, Van Esch H, Willett C, Woszczek G.

Drug Discov Today. 2017 Feb;22(2):327-339. doi: 10.1016/j.drudis.2016.10.011. Epub 2016 Oct 29. Review.

9.

Cytostretch, an Organ-on-Chip Platform.

Gaio N, van Meer B, Quirós Solano W, Bergers L, van de Stolpe A, Mummery C, Sarro PM, Dekker R.

Micromachines (Basel). 2016 Jul 14;7(7). pii: E120. doi: 10.3390/mi7070120.

10.

Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing.

Marx U, Andersson TB, Bahinski A, Beilmann M, Beken S, Cassee FR, Cirit M, Daneshian M, Fitzpatrick S, Frey O, Gaertner C, Giese C, Griffith L, Hartung T, Heringa MB, Hoeng J, de Jong WH, Kojima H, Kuehnl J, Leist M, Luch A, Maschmeyer I, Sakharov D, Sips AJ, Steger-Hartmann T, Tagle DA, Tonevitsky A, Tralau T, Tsyb S, van de Stolpe A, Vandebriel R, Vulto P, Wang J, Wiest J, Rodenburg M, Roth A.

ALTEX. 2016;33(3):272-321. doi: 10.14573/altex.1603161. Epub 2016 May 15. Review.

11.

Pan-cancer subtyping in a 2D-map shows substructures that are driven by specific combinations of molecular characteristics.

Taskesen E, Huisman SM, Mahfouz A, Krijthe JH, de Ridder J, van de Stolpe A, van den Akker E, Verheagh W, Reinders MJ.

Sci Rep. 2016 Apr 25;6:24949. doi: 10.1038/srep24949. Erratum in: Sci Rep. 2018 Nov 23;8(1):17304.

12.

Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research.

Langley G, Austin CP, Balapure AK, Birnbaum LS, Bucher JR, Fentem J, Fitzpatrick SC, Fowle JR 3rd, Kavlock RJ, Kitano H, Lidbury BA, Muotri AR, Peng SQ, Sakharov D, Seidle T, Trez T, Tonevitsky A, van de Stolpe A, Whelan M, Willett C.

Environ Health Perspect. 2015 Nov;123(11):A268-72. doi: 10.1289/ehp.1510345.

13.

Knowledge-based computational models.

Verhaegh W, Van de Stolpe A.

Oncotarget. 2014 Jul 30;5(14):5196-7. No abstract available.

14.

Circulating Tumor Cells: What Is in It for the Patient? A Vision towards the Future.

van de Stolpe A, den Toonder JM.

Cancers (Basel). 2014 May 28;6(2):1195-207. doi: 10.3390/cancers6021195.

15.

Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways.

Verhaegh W, van Ooijen H, Inda MA, Hatzis P, Versteeg R, Smid M, Martens J, Foekens J, van de Wiel P, Clevers H, van de Stolpe A.

Cancer Res. 2014 Jun 1;74(11):2936-45. doi: 10.1158/0008-5472.CAN-13-2515. Epub 2014 Apr 2.

16.

Workshop meeting report Organs-on-Chips: human disease models.

van de Stolpe A, den Toonder J.

Lab Chip. 2013 Sep 21;13(18):3449-70. doi: 10.1039/c3lc50248a.

PMID:
23645172
17.

On the origin and destination of cancer stem cells: a conceptual evaluation.

van de Stolpe A.

Am J Cancer Res. 2013;3(1):107-16. Epub 2013 Jan 18.

18.

Design and pharmacological characterization of VUF14480, a covalent partial agonist that interacts with cysteine 98(3.36) of the human histamine H₄ receptor.

Nijmeijer S, Engelhardt H, Schultes S, van de Stolpe AC, Lusink V, de Graaf C, Wijtmans M, Haaksma EE, de Esch IJ, Stachurski K, Vischer HF, Leurs R.

Br J Pharmacol. 2013 Sep;170(1):89-100. doi: 10.1111/bph.12113.

19.

Catechol pyrazolinones as trypanocidals: fragment-based design, synthesis, and pharmacological evaluation of nanomolar inhibitors of trypanosomal phosphodiesterase B1.

Orrling KM, Jansen C, Vu XL, Balmer V, Bregy P, Shanmugham A, England P, Bailey D, Cos P, Maes L, Adams E, van den Bogaart E, Chatelain E, Ioset JR, van de Stolpe A, Zorg S, Veerman J, Seebeck T, Sterk GJ, de Esch IJ, Leurs R.

J Med Chem. 2012 Oct 25;55(20):8745-56. doi: 10.1021/jm301059b. Epub 2012 Oct 8.

PMID:
22963052
20.

Molecular determinants of ligand binding modes in the histamine H(4) receptor: linking ligand-based three-dimensional quantitative structure-activity relationship (3D-QSAR) models to in silico guided receptor mutagenesis studies.

Istyastono EP, Nijmeijer S, Lim HD, van de Stolpe A, Roumen L, Kooistra AJ, Vischer HF, de Esch IJ, Leurs R, de Graaf C.

J Med Chem. 2011 Dec 8;54(23):8136-47. doi: 10.1021/jm201042n. Epub 2011 Nov 7.

PMID:
22003888
21.

Circulating tumor cell isolation and diagnostics: toward routine clinical use.

van de Stolpe A, Pantel K, Sleijfer S, Terstappen LW, den Toonder JM.

Cancer Res. 2011 Sep 15;71(18):5955-60. doi: 10.1158/0008-5472.CAN-11-1254. Epub 2011 Sep 6.

22.

Prediction of drug-induced cardiotoxicity using human embryonic stem cell-derived cardiomyocytes.

Braam SR, Tertoolen L, van de Stolpe A, Meyer T, Passier R, Mummery CL.

Stem Cell Res. 2010 Mar;4(2):107-16. doi: 10.1016/j.scr.2009.11.004. Epub 2009 Dec 3.

23.

Clobenpropit analogs as dual activity ligands for the histamine H3 and H4 receptors: synthesis, pharmacological evaluation, and cross-target QSAR studies.

Lim HD, Istyastono EP, van de Stolpe A, Romeo G, Gobbi S, Schepers M, Lahaye R, Menge WM, Zuiderveld OP, Jongejan A, Smits RA, Bakker RA, Haaksma EE, Leurs R, de Esch IJ.

Bioorg Med Chem. 2009 Jun 1;17(11):3987-94. doi: 10.1016/j.bmc.2009.04.007. Epub 2009 Apr 11.

PMID:
19414267
24.

Cardiomyocytes from human and mouse embryonic stem cells.

Mummery C, van der Heyden MA, de Boer TP, Passier R, Ward D, van den Brink S, van Rooijen M, van de Stolpe A.

Methods Mol Med. 2007;140:249-72.

PMID:
18085213
25.

Antinociceptive activity of furan-containing congeners of improgan and ranitidine.

Hough LB, Menge WM, van de Stolpe AC, Nalwalk JW, Leurs R, de Esch IJ.

Bioorg Med Chem Lett. 2007 Oct 15;17(20):5715-9. Epub 2007 Aug 19.

26.

Human embryonic stem cells: towards therapies for cardiac disease. Derivation of a Dutch human embryonic stem cell line.

van de Stolpe A, van den Brink S, van Rooijen M, Ward-van Oostwaard D, van Inzen W, Slaper-Cortenbach I, Fauser B, van den Hout N, Weima S, Passier R, Smith N, Denning C, Mummery C.

Reprod Biomed Online. 2005 Oct;11(4):476-85.

PMID:
16274613
27.

Synthesis and structure-activity relationship of 3-phenyl-3H-quinazolin-4-one derivatives as CXCR3 chemokine receptor antagonists.

Storelli S, Verdijk P, Verzijl D, Timmerman H, van de Stolpe AC, Tensen CP, Smit MJ, De Esch IJ, Leurs R.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2910-3.

PMID:
15911279
28.

Estrogen receptor (ER)-mediated transcriptional regulation of the human corticotropin-releasing hormone-binding protein promoter: differential effects of ERalpha and ERbeta.

van de Stolpe A, Slycke AJ, Reinders MO, Zomer AW, Goodenough S, Behl C, Seasholtz AF, van der Saag PT.

Mol Endocrinol. 2004 Dec;18(12):2908-23. Epub 2004 Sep 2.

PMID:
15345745
29.

[From gene to disease; risk factors for venous thrombosis: factor V Leiden and prothrombin 20210A].

Reitsma PH, van de Stolpe A.

Ned Tijdschr Geneeskd. 2001 Sep 22;145(38):1843-5. Review. Dutch.

PMID:
11593787
30.

Synthesis and use of FSCPX, an irreversible adenosine A1 antagonist, as a 'receptor knock-down' tool.

van Muijlwijk-Koezen JE, Timmerman H, van der Sluis RP, van de Stolpe AC, Menge WM, Beukers MW, van der Graaf PH, de Groote M, IJzerman AP.

Bioorg Med Chem Lett. 2001 Mar 26;11(6):815-8.

PMID:
11277527
31.

Synthesis and structure-activity relationships of carboxyflavones as structurally rigid CysLT1 (LTD4) receptor antagonists.

Zwaagstra ME, Timmerman H, van de Stolpe AC, de Kanter FJ, Tamura M, Wada Y, Zhang MQ.

J Med Chem. 1998 Apr 23;41(9):1428-38.

PMID:
9554876
32.

NF-kappa B/Rel family members regulating the ICAM-1 promoter in monocytic THP-1 cells.

Wissink S, van de Stolpe A, Caldenhoven E, Koenderman L, van der Saag PT.

Immunobiology. 1997 Dec;198(1-3):50-64.

PMID:
9442377
33.

Molecular mechanisms of steroid action: a novel type of cross-talk between glucocorticoids and NF-kappa B transcription factors.

van der Saag PT, Caldenhoven E, van de Stolpe A.

Eur Respir J Suppl. 1996 Aug;22:146s-153s.

PMID:
8871061
34.

Intercellular adhesion molecule-1.

van de Stolpe A, van der Saag PT.

J Mol Med (Berl). 1996 Jan;74(1):13-33. Review.

PMID:
8834767
35.

Fibrinogen binding to ICAM-1 on EA.hy 926 endothelial cells is dependent on an intact cytoskeleton.

van de Stolpe A, Jacobs N, Hage WJ, Tertoolen L, van Kooyk Y, Nováková IR, de Witte T.

Thromb Haemost. 1996 Jan;75(1):182-9.

PMID:
8713799
36.

Negative cross-talk between RelA and the glucocorticoid receptor: a possible mechanism for the antiinflammatory action of glucocorticoids.

Caldenhoven E, Liden J, Wissink S, Van de Stolpe A, Raaijmakers J, Koenderman L, Okret S, Gustafsson JA, Van der Saag PT.

Mol Endocrinol. 1995 Apr;9(4):401-12.

PMID:
7659084
37.
38.

Stimulation of the human intercellular adhesion molecule-1 promoter by interleukin-6 and interferon-gamma involves binding of distinct factors to a palindromic response element.

Caldenhoven E, Coffer P, Yuan J, Van de Stolpe A, Horn F, Kruijer W, Van der Saag PT.

J Biol Chem. 1994 Aug 19;269(33):21146-54.

39.
40.

Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines.

van de Stolpe A, Caldenhoven E, Raaijmakers JA, van der Saag PT, Koenderman L.

Am J Respir Cell Mol Biol. 1993 Mar;8(3):340-7.

PMID:
8095395
41.

Parathyroid hormone-related peptide as an endogenous inducer of parietal endoderm differentiation.

van de Stolpe A, Karperien M, Löwik CW, Jüppner H, Segre GV, Abou-Samra AB, de Laat SW, Defize LH.

J Cell Biol. 1993 Jan;120(1):235-43.

42.

Effects of atrial natriuretic peptide on distal tubule function in humans.

Rabelink TJ, Koomans HA, van de Stolpe A, Bijlsma JA, Dorhout Mees EJ.

Kidney Int. 1990 Mar;37(3):996-1001.

43.

Micropuncture study of the effect of ANP on the papillary collecting duct in the rat.

van de Stolpe A, Jamison RL.

Am J Physiol. 1988 Apr;254(4 Pt 2):F477-83.

PMID:
2965515
44.

Total body potassium in Bartter's syndrome before and during treatment with enalapril.

van de Stolpe A, Verhoef GE, Hené RJ, Koomans HA, van der Vijver JC.

Nephron. 1987;45(2):122-5.

PMID:
3031521

Supplemental Content

Loading ...
Support Center